文献速递临床试验与 GCP

他达拉非联合低强度脉冲超声治疗勃起功能障碍的疗效评估:一项随机对照试验方案(符合SPIRIT声明)

Evaluation of tadalafil in combination with Low-Intensity Pulsed Ultrasound (LIPUS) for erectile dysfunction: a protocol for a randomized controlled trial (SPIRIT Compliant).
PubMed 文献 · Trials · 2025-11-25

本研究为一项随机对照试验方案,计划纳入114例勃起功能障碍患者,按1:1随机分为治疗组和对照组。治疗组接受他达拉非5 mg每日联合低强度脉冲超声(LIPUS)每周两次治疗4周,间隔4周单用他达拉非5 mg每日后再重复联合方案;对照组仅接受他达拉非5 mg每日。主要结局采用基于IIEF-5的最小临床重要差异(MCID)评估,并纳入EHS、阴茎血流参数及弹性值。

要点

  • 拟纳入114例ED患者,1:1随机分为他达拉非联合LIPUS组与单用他达拉非组。
  • 治疗组方案为4周联合治疗(他达拉非5 mg每日+LIPUS每周两次),间隔4周单药后再重复。
  • 主要结局为基于IIEF-5的MCID,次要评估包括EHS、阴茎血流参数及弹性值。

核心结论

  • 研究旨在评估他达拉非联合LIPUS治疗ED的疗效,并通过整合血流参数与二维剪切波弹性成像改进ED治疗反应的评估。

研究设计与样本

  • 随机对照试验方案,计划纳入114例诊断为ED的患者,采用简单随机抽样按1:1比例随机分配至治疗组或对照组。

主要发现

  • 原文未报告研究结果。

关键数值与推荐

  • 治疗组先接受他达拉非5 mg每日联合LIPUS每周两次治疗4周,随后间隔4周单用他达拉非5 mg每日(不做LIPUS),再重复同一联合方案。
  • 对照组仅接受他达拉非5 mg每日。
  • 主要结局采用基于IIEF-5的最小临床重要差异(MCID),于每次随访时评估。
  • 附加评估包括勃起硬度评分(EHS)、阴茎血流参数及弹性值。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Erectile dysfunction (ED) is characterized by a persistent inability to achieve and maintain sufficient penile erection for satisfactory sexual performance persisting for at least six months. Low-intensity pulsed ultrasound (LIPUS), a noninvasive therapy, has shown potential in improving ED by promoting the regeneration of connective tissue, blood vessels, and cavernous nerves, as well as reducing inflammation. This study aims to evaluate the clinical efficacy and histological changes in the corpus cavernosum of patients with ED treated with tadalafil combined with LIPUS through a randomized controlled trial. METHODS: This study will enroll 114 patients diagnosed with ED who will be randomly assigned to either the treatment group or the control group in a 1:1 ratio using simple random sampling. The treatment group will first receive 5 mg of tadalafil daily combined with twice-weekly LIPUS therapy for 4 weeks. Following a 4-week interval with daily 5 mg tadalafil alone (no LIPUS treatment), the same combined treatment regimen will be repeated. The control group will receive only 5 mg of tadalafil daily. The primary outcome will be assessed using the minimal clinically important difference (MCID) based on the International Index of Erectile Function-5 (IIEF-5) at each follow-up visit. Additional assessments will include the Erection Hardness Score (EHS), penile blood flow parameters, and elasticity values for a comprehensive evaluation. DISCUSSION: The study aims to evaluate the efficacy of tadalafil combined with LIPUS for treating ED and to improve the evaluation of treatment response in erectile dysfunction by integrating blood flow parameters and two-dimensional shear wave elastography. TRIAL REGISTRATION: Trial registration: ClinicalTrials.gov, NCT06543628. Registered 5th August 2024, https://clinicaltrials.gov/study/NCT06543628 .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Zhang Q, Lv B, Yu H, et al. Evaluation of tadalafil in combination with Low-Intensity Pulsed Ultrasound (LIPUS) for erectile dysfunction: a protocol for a randomized controlled trial (SPIRIT Compliant). Trials. 2025. PMID: 41291823. doi:10.1186/s13063-025-09298-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。